Tobacco Smoke Exposure Reduces Paraoxonase Activity in a Murine Model

Robert M. Reed¹, Saif M. Borgan¹, Michael Eberlein², Monica Goldklang³, Joshua Lewis⁴, Michael Miller⁵, Mohamad Navab⁶, Bo S. Kim⁷

¹University of Maryland School of Medicine, Division of Pulmonary and Critical Care Medicine, 110 South Paca Street, 2nd Floor, Baltimore, Maryland 21201, United States; ²University of Iowa School of Medicine, Division of Pulmonary and Critical Care Medicine, C326 GH Iowa City, Iowa 52242, United States; ³Division of Anesthesia, Columbia University, Anesthesiology, New York, New York, United States; ⁴Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Howard Hall, 498, Maryland, United States; ⁵Division of Cardiology, University of Maryland School of Medicine, 110 South Paca Street, Baltimore, Maryland 21201, United States; ⁶David Geffen School of Medicine, Division of Cardiology, Le Conte Ave, Los Angeles, California 90095, United States; ⁷Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument Street, Baltimore, Maryland 21287, United States

ABSTRACT

AIM: To demonstrate a direct inhibitory effect of cigarette smoke exposure on paraoxonase 1 activity in a murine in vivo model. METHODS: At 8 weeks old, we randomized 10 C57/bl6 mice to an environment consisting of either filtered air or cigarette smoke for 6 months. Smoke exposure (7 hours per day, 5 days per week) was standardized using a model TE-10 smoking machine and adjusted to maintain constant sidestream and mainstream smoke. After 6 months of exposure, we assessed differences in lung air space, cholesterol, lipid, and lipoprotein profiles, as well as paraoxonase activity in mice exposed to cigarette smoke extract compared to unexposed control mice. RESULTS: Cigarette smoke exposure by the protocol used was sufficient to result in pathologic changes in lung architecture consistent with emphysema. Specifically, we observed that mice exposed to cigarette smoke had a significantly higher mean linear chord length compared to animals that were exposed to filtered air (p<0.02). Despite this exposure, no differences in total HDL-cholesterol levels or HDL-cholesterol sub-fractions (i.e. HDL2 and HDL3 fractions) were noted between smoke-exposed and unexposed animals (p=1.00, 0.6, and 0.4, respectively). Notably, mean HDL-cholesterol levels were identical between groups (92.8 vs 92.8 mg/dL, p=1.0). Paraoxonase activity, however, was markedly reduced in mice exposed to cigarette smoke compared to those who were not exposed (102, SD=9.6 vs 144, SD=4.1 units of activity, respectively, p=0.002). CONCLUSION: In this murine model, tobacco smoke exposure directly inhibits paraoxonase activity independently of HDL-cholesterol levels rather than indirectly via reduction in HDL-cholesterol levels. (Int J Biomed Sci 2017; 13 (1): 20-25)

Keywords: Paraoxonase; High density lipoprotein; tobacco smoke; antioxidants

Corresponding author: Robert M. Reed, MD, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, 110 South Paca Street, 2nd Floor, Baltimore, Maryland 21201. Tel: 410-328-8141; Fax: 410-328-0177; E-mail: rreed@medicine.umaryland.edu.

Author contributions: Reed RM drafted the manuscript and all authors participated in revision of the manuscript with approval of the final version.

Received December 12, 2016; Accepted February 16, 2017

Copyright: © 2017 Robert M. Reed et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
INTRODUCTION

In 1946, Mazur et al described an endogenous enzyme that is capable of inactivating a group of bioactive, potentially toxic chemicals known as organophosphates (1). This enzyme is now identified as paraoxonase (PON) and research is still underway to unravel the full spectrum of its properties, including its anti-oxidant, anti-inflammatory and anti-cholinergic actions (2). Three subclasses of the PON family have been discovered (PON1, PON2 and PON3), with variations in their function and potency. All PON enzymes share similar anti-oxidant properties, but unlike its counterparts, PON2 lacks any activity against organophosphate. The inhibitory action of PON1, and to a lesser extent PON3, on organophosphates was one of the first described functions of the PON family and is significant when considering the effects of organophosphates on the body. Organophosphates are a class of bioactive chemicals first described around 1850 by Philippe de Ciermont, but not appreciated to be toxic until the 1930s (3). Organophosphate toxicity manifests through strong anticholinergic effects, and organophosphates are used in a variety of applications including as pesticides and as biological weapons such as sarin gas. Consistent with its in vitro ability to inactivate organophosphates, lower PON activity as well as genetic variants associated with lower PON activity are associated with increased susceptibility to organophosphate poisoning (4).

Paraoxonase 1 is a calcium-dependent enzyme produced primarily in the liver and circulates the body in association with high density lipoprotein (HDL) (2). PON1 is thought to exhibit various anti-atherosclerotic properties through inactivation of oxidized low density lipoprotein (LDL), stimulation of HDL-mediated cholesterol efflux from macrophages, and suppression of monocyte transformation into foam cells (2, 5).

Several cross-sectional studies studies have shown tobacco smoking to correlate with lower PON activity (2, 6-9). In those studies, smoking was also associated with lower levels of HDL-cholesterol which in turn correlate strongly with PON1 activity. While statistical analyses indicated the reductions in HDL-cholesterol seemed at least partially independent, the possibility for unmeasured confounding remain. While in vitro studies clearly demonstrate PON1 inhibition by cigarette smoke extract directly, to our knowledge controlled in vivo studies are lacking.

Thus we sought to characterize PON levels and lipid profiles associated with tobacco smoke exposure in a murine model in order to evaluate the hypothesis that PON reductions in vivo occur primarily through direct effects with little indirect effect attributable to reduced HDL levels.

MATERIALS AND METHODS

Murine cigarette exposure

Smoke exposure was performed as previously described (10). In brief, 10 C57/bl6 mice were randomized at 8 weeks of age to receive either filtered air or cigarette smoke exposure for 7 hours a day, 5 days a week. Smoke was generated using Kentucky 3R4F cigarettes (Tobacco Research Institute, University of Kentucky, Lexington, KY, USA) in a model TE-10 smoking machine (Teague Enterprises, Woodland, CA, USA). Each cigarette was puffed for seconds every minute for a total of 8 puffs, at a flow rate of 1.05 L/min to generate a standard 35 mL puff. Exposure was adjusted to maintain a mixture of 89% side-stream smoke and 11% mainstream smoke. After 6 months of exposure, mice were removed from smoke for over 24 hours and then sacrificed to permit collection of serum and lung samples. Emphysematous changes were quantified by measuring mean linear chord length as an index of airspace size (11).

Lipid profiles

Cholesterol levels were measured using the vertical auto profile method, which is a density gradient ultracentrifugation technique (12). Paraoxonase activity was measured as previously described (13, 14). Detailed methods for paraoxonase measures are included in methods supplement #1, #2.

Statistical analysis

Data are presented as means (standard deviation). Comparisons between mice exposed to cigarette smoke and filtered air were made using Student t tests. Data were analyzed using STATA 14 SC software (StataCorp-LP, College Station, TX, USA). For all analyses, two-tailed p<0.05 was considered significant.

RESULTS

Consistent with previous reporting (10), cigarette smoke exposure by the protocol used was sufficient to result in pathologic changes in lung architecture consistent with emphysema (Figure 1). Specifically, we observed that mice exposed to cigarette smoke had a significantly higher mean linear chord length compared to animals that were exposed to filtered air (p<0.02). Importantly, however, no differences in total HDL-cholesterol levels...
or HDL-cholesterol sub-fractions (i.e. HDL2 and HDL3 fractions) were noted between smoke-exposed and unexposed animals ($p=1.00, 0.6, \text{ and } 0.4$, respectively). In addition, serum LDL and very low-density lipoprotein (VLDL) levels were similar between intervention groups ($P=0.09, 0.07, \text{ and } 0.2$ for levels of LDL, VLDL, and VLDL3, respectively). Complete analysis of lipid profiles between mice exposed to cigarette smoke and control mice are shown in Table 1. Notably, mean HDL-C levels were identical between groups (92.8 vs 92.8 mg/dL, $p=1.0$). Paraoxonase activity however, was significantly lower in the smoke exposed group compared to control animals (102 vs 144 units of activity, respectively, $p=0.002$) (Figure 2).

**DISCUSSION**

In this investigation, we observed that mice exposed to cigarette smoke had markedly reduced paraoxonase activity compared to control mice despite the fact that mean HDL-cholesterol levels were identical.

**Table 1.** Lipid profiles of mice exposed to either filtered air or cigarette tobacco smoke for 6 months

|                          | Air             | Tobacco Smoke | P   |
|--------------------------|-----------------|---------------|-----|
| Total Cholesterol (mg/dL)| 153.6 (15.4)    | 142.2 (16.3)  | 0.4 |
| HDL Cholesterol (mg/dL)  | 92.8 (6.1)      | 92.8 (9.8)    | 1.0 |
| Non-HDL Cholesterol (mg/dL) | 61.0 (9.4)  | 49.4 (34.1)   | 0.1 |
| HDL2 Cholesterol (mg/dL) | 28.8 (4.5)      | 30.6 (6.9)    | 0.6 |
| HDL3 Cholesterol (mg/dL) | 64.0 (2.9)      | 62.2 (3.3)    | 0.4 |
| Lp(a) Cholesterol (mg/dL)| 16.4 (4.5)      | 11.4 (3.4)    | 0.08|
| Total LDL (LDL-R + Lp(a) + IDL Cholesterol) (mg/dL) | 48.2 (9.3) | 35.4 (11.5)  | 0.09|
| LDL-R (mg/dL)           | 34.4 (5.3)      | 26.4 (7.6)    | 0.09|
| VLDL Cholesterol (mg/dL)| 12.8 (0.4)      | 14 (1.2)      | 0.07|

HDL, high density lipoprotein; IDL, intermediate density lipoprotein; Lp, lipoprotein; LDL, low density lipoprotein; LDL-R, real low density lipoprotein. Data are expressed as mean (SD).
Our findings indicate that the magnitude of direct effect on PON levels that cigarette exposure exerts seems considerably greater than the magnitude of effect the same exposure manifests on HDL-cholesterol levels. Notably, our data should not be taken to suggest that smoke exposure does not result in reduced HDL-cholesterol as this is well established in both humans as well as murine models (15-17). The lack of reduction in HDL-cholesterol levels was not expected and may be explained by inadequate power in our sample. Importantly, however, our findings do indicate that cigarette smoke exposure seems to directly inhibit PON1 activity independently of HDL-cholesterol levels. While previous investigations show that a reduction in HDL-cholesterol levels do lead to a concomitant decrease in PON1 activity (2), the magnitude of direct effect on PON levels that cigarette exposure exerts seems considerably greater than the magnitude of effect attributable to tobacco smoke related reductions in HDL-cholesterol levels.

A less-likely alternate hypothesis as to why cigarette exposure failed to result in a reduced HDL-cholesterol level relates to the emphysematous changes observed. Studies primarily including former smokers have observed a correlation between emphysema and elevated levels of HDL-cholesterol (18-23). As such, it is difficult to exclude the possibility that the cigarette smoke related reduction in HDL-cholesterol levels was mitigated by the development of emphysema.

Since PON has anti-atherosclerotic effects, the direct inhibitory effects of tobacco smoke on PON activity, regardless of HDL level, may help to explain the excess cardiovascular disease (CVD) risk observed in chronic obstructive pulmonary disease (COPD). Several studies have suggested that HDL does not always reduce cardiovascular risk (24-26). This is thought due to periodic conversion of HDL to a pro-inflammatory state characterized by low PON1 activity (25-27).

The frequent coexistence of COPD and CVD is not fully explained by traditional risk factors including smoking and lipid levels (22, 28-37). The mechanisms of this association are unknown, and the association persists in patients who have never smoked (32, 37). A hypothesis that stems from our findings in context with the literature available is that PON activity may in large part explain this observation. Genetically determined variations in PON activity have been implicated in not only cardiovascular, but also pulmonary function (2). In addition to its role as an HDL-associated multifunctional antioxidant enzyme, PON1 is also found in non-ciliated bronchiolar epithelial (Clara) and type 1 alveolar cells of the lung as well as in the vascular endothelium. Data suggest that PON1 protects the airway epithelium as well as vascular endothelium through anti-oxidative and anti-inflammatory effects, and that it is integral to the cardio-protective properties of HDL. Reduced PON1 activity impairs the normal function of HDL to remove oxidized phospholipids. Such oxidized phospholipids facilitate the recruitment and activation of monocytes to the vascular intima (25, 27, 38, 39). HDL is also known to exert anti-inflammatory effects in the lung (40). However, since COPD has been associated with both, high HDL levels (18-23) and high rates of CVD (22, 28-37), this discrepancy could be explained by a dysfunctional HDL mechanism in this population. Our prior data suggest high HDL-cholesterol in this population does not associate with reduced cardiovascular disease (22), and reduced paraoxonase activity has been described in association with COPD (41). Notably, paraoxonase levels in smokers without COPD were not reduced (41) and are strongly affected by genetic polymorphisms (41, 42). These polymorphisms in turn have been implicated in susceptibility to COPD (41, 43) as well as cardiovascular disease (44).

The strength of our conclusions is limited by the sample size, which could not be increased due to the closure of the lab (Atherotec Diagnostics Lab) where lipid studies were performed. Consequently the robustness of the findings are limited and the results warrant replication.

CONCLUSIONS

In a murine model, tobacco smoke exposure was associated with lower levels of paraoxonase activity despite no differences in HDL-cholesterol levels compared to control mice. This suggests that tobacco smoke exposure primarily acts directly to reduce paraoxonase levels rather than indirectly via reduction in HDL-cholesterol levels.

COMMENTS

Background

Paraoxonase 1 (PON1) is an enzyme that binds to high density lipoprotein (HDL) particles and imparts anti-oxidant and antiatherogenic properties. Cigarette smoke exposure is associated with reduced PON1 activity in cross-sectional correlative studies through what appears to be both direct effects as well as indirect effects as a result of a smoking related reduction in HDL particles. In vivo administration of cigarette smoke further supports a direct inhibitory effect. We sought to demonstrate a direct inhibi-
tory effect of cigarette smoke exposure on PON1 activity in a murine in vitro model.

Research frontiers
Lung function and vascular disease demonstrate correlation that is independent of common risk factors, such as tobacco smoke exposure. The mechanisms of that associated are incompletely understood and paraoxonase is a plausible target for future study.

Innovations and breakthroughs
We demonstrated a reduction in paraoxonase activity associated with tobacco smoke exposure despite no differences in HDL-cholesterol levels in a murine model. This suggests that tobacco smoke exposure primarily acts directly to reduce paraoxonase levels rather than indirectly via reduction in HDL-cholesterol levels. Due to the small sample size, results warrant replication.

Applications
As paraoxonase 1 has been correlated to both lung and vascular function, it represents a plausible intermediary warranting further study as a biomarker, and may pose a novel target for future therapeutics.

REFERENCES
1. Mazur A. An enzyme in animal tissues capable of hydrolysing the phosphorus-fluorine bond of alkyl fluorophosphates. J. Biol. Chem. 1946; 164: 271-289.
2. Milnerowicz H, Kowalska K, Socha E. Paraoxonase activity as a marker of exposure to xenobiotics in tobacco smoke. Int. J. Toxicol. 2015; 34: 224-232.
3. Petroianu GA. Toxicity of phosphor esters: Willy Lange (1900-1976) and Gerda von Krueger (1907-after 1970). Pharmazie. 2010; 65: 776-780.
4. Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet. 2002; 359: 763-764.
5. Rosenblat M, Gaidukov L, Khersonsky O, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 2006; 281: 7657-7665.
6. Haj MD, Ezzaher A, Mechri A, et al. Effect of cigarette smoking on paraoxonase 1 activity according to PON1 L55M and PON1 Q192R gene polymorphisms. Environ Health Prev. Med. 2012; 17: 316-321.
7. Senti M, Tomas M, et al. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur. J. Intern. Med. 2003; 14: 178-184.
8. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation. 2000; 101: 2252-2257.
9. Ferre N, Camps J, Fernandez-Ballart J, et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 2003; 49:1491-1497.
10. Kim BS, Serebreni L, Hamdan O, et al. Xanthine oxidoreductase is a critical mediator of cigarette smoke-induced endothelial cell DNA damage and apoptosis. Free Radic. Biol. Med. 2013; 60: 336-346.
11. Escolar JD, Gallego B, Tejero C, Escolar MA. Changes occurring with increasing age in the rat lung: morphometrical study. Anat. Rec. 1994; 239: 287-296.
12. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin. Lab. Med. 2006; 26: 787-802.
13. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 1995; 96: 2758-2767.
14. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 1991; 19: 100-106.
15. Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention. 2010.
16. Koul A, Singh A, Sandhir R. Effect of alpha-tocopherol on the cardiac antioxidant defense system and atherogenic lipids in cigarette smoke-inhaling mice. Inhal Toxicol. 2003; 15: 513-522.
17. Zong C, Song G, Yao S, et al. Cigarette smoke exposure impacts reverse cholesterol transport which can be minimized by treatment of hydrogen-saturated saline. Lipids Health Dis. 2015; 14: 159.
18. Seishima M, Mori A, Torizawa H, Muto Y. Hyper-HDL-cholesterolemia in patients with chronic pulmonary insufficiency. Rinsho Byori. 1988; 36: 318-322.
19. Tisi GM, Conrique A, Barrett-Connor E, Grundy SM. Increased high density lipoprotein cholesterol in obstructive pulmonary disease (dominant emphysematous type). Metabolism. 1981; 30: 340-346.
20. Bolton CH, Muller E, Harvey J, Downs LG, et al. Plasma and lipoprotein lipids and apolipoproteins A1, AII and B in patients with chronic airflow limitation. J R Soc. Med. 1989; 82: 91-92.
21. Reed RM, Wise RA, Dobs AS, Lechtenb N, et al. Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease. Respir Med. 2010; 104: 1943-1950.
22. Reed RM, Iacono A, Defilippis A, Eberlein M, et al. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J. Heart Lung Transplant. 2011; 30: 674-678.
23. Reed RM, Hashmi S, Eberlein M, et al. Impact of lung transplantation on serum lipids in COPD. Respir Med. 2011; 105: 1961-1968.
24. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein-cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 2008; 51: 634-642.
25. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb. Vasc. Biol. 2001; 21: 481-488.
26. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 2007; 356: 1620-1630.
27. Navab M, Ananthamadiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 2004; 45: 993-1007.
28. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary dis-
ease as an independent risk factor for cardiovascular morbidity. *Int. J. Chron. Obstruct Pulmon Dis.* 2009; 4: 337-349.

29. Macnee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. *Proc. Am. Thorac Soc.* 2008; 5: 824-833.

30. Sin DD, Man SF. Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. *Curr. Opin. Pulm. Med.* 2008; 14: 115-121.

31. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. *Chest.* 2005; 127: 1952-1959.

32. Hole DJ, Watt GC, Davey-Smith G, Hart CL, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ.* 1996; 313: 711-715.

33. Ebi-Kryston KL. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. *J. Clin. Epidemiol.* 1988; 41: 251-260.

34. Persson C, Bengtsson C, Lapidious L, Rybo E, et al. Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. *Am. J. Epidemiol.* 1986;124:942-948.

35. Truelsen T, Prescott E, Lange P, Schnohr P, et al. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. *Int. J. Epidemiol.* 2001; 30: 145-151.

36. Sorlie PD, Kannel WB, O’Connor G. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. *Am. Rev. Respir Dis.* 1989; 140: 379-384.

37. Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. *Eur. Respir J.* 2012; 39: 846-854.

38. Leitinger N, Tyner TR, Oslund L, et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. *Proc. Natl. Acad. Sci. USA.* 1999; 96: 12010-12015.

39. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. *J. Clin. Invest.* 2011; 121: 2693-2708.

40. Fioretino M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. *Curr. Opin. Cardiol.* 2008; 23: 370-378.

41. Tekes S, Isik B, Yildiz T, Simsek S, et al. Chronic Obstructive Pulmonary Disease and Paraoxonase-1 192 and 55 Gene Polymorphisms. *Biotechnol & Biotechnol EQ.* 2010; 24: 1644-1647.

42. Thyagarajan B, Jacobs DR, Jr., Carr JJ, et al. Factors associated with paraoxonase genotypes and activity in a diverse, young, healthy population: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Clin. Chem.* 2008; 54: 738-746.

43. Seo T, Pahwa P, McDuffie HH, et al. Interactive effect of paraoxonase-1 Q192R polymorphism and smoking history on the lung function decline in grain workers. *Ann. Epidemiol.* 2008; 18: 330-334.

44. Zhao Y, Ma Y, Fang Y, et al. Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. *Mol. Genet Metab.* 2012; 105: 141-148.